Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
Trial details
- Registry ID
- NCT07637162
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as AXS-14; esreboxetine
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Open-Label Safety Study of AXS-14 in Subjects With FibromyalgiaNCT07637162 | AXSM | Phase 3 | Enrolling by invitation | 2028-05Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |